IGC Pharma Receives Higher Price Target as Alzheimer’s Trial Advances

Jun 10, 2026

IGC Pharma announced that Ascendant Capital Markets has issued an updated equity research report on the company, raising its price target to $5.50 per share. According to the report, continued clinical progress and upcoming milestones could serve as important catalysts as the company advances its Alzheimer’s disease treatment programs.

IGC Pharma’s lead candidate, IGC-AD1, is currently being evaluated in the Phase 2 CALMA clinical trial for agitation associated with Alzheimer’s disease. The company continues to move the study toward key operational and clinical milestones as it works to address a significant unmet need in neurological healthcare.

#IGCPharma
#AlzheimersDisease
#Biotech
#ClinicalTrials
#HealthcareInnovation
#MedicalResearch
#Neurology
#DrugDevelopment
#Alzheimers
#Healthcare
#StockMarket
#Biotechnology
#InvestorNews
#JaneKing
#NewsOut